Mycobacteroides abscessus

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024

Retrieved on: 
Thursday, April 18, 2024
Infection, University of Southern California, Medical microbiology, University, Mycobacteroides abscessus, Tuberculosis, Epidemiology, ESCMID, ECCMID, Erasmus MC, Urinary tract infection, Science, MAC, Antimycobacterial, Mycobacterium avium complex, Clinical pharmacy, Immunity, TB, National Jewish Health, Division, Pharmaceutical industry

BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).

Key Points: 
  • BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA® (omadacycline) will be presented at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global, formerly ECCMID).
  • The hybrid conference will be held April 27-30 at the Fira Gran Via in Barcelona, Spain.
  • “Paratek continues to invest in science to further our understanding of NUZYRA, as well as explore its future utility in addressing additional unmet patient needs,” said Randy Brenner, chief development and regulatory officer of Paratek.
  • “Next week’s ESCMID presentations include a study assessing the potential immunomodulating properties of NUZYRA in addition to its antibacterial activity.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, Administration, Nontuberculous mycobacteria, Conference, Bill, AN2, Entrepreneurship, NTM, Boron, Tuberculosis, University, Patient, Melioidosis, Data monitoring committee, G&A, MAC, Insurance, Infection, Wellcome Trust, Investment, Clinical trial, Chagas disease, Therapy, Malaria, Safety, Poster, Research and development, Mycobacteroides abscessus, IDSA, Trust, Pharmaceutical industry

Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.

Key Points: 
  • Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer.
  • Net loss: Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year.
  • Net loss for the fourth quarter of 2023 was $16.9 million, compared to $11.8 million for the same period during 2022.
  • Cash Position: The Company had cash, cash equivalents, and investments of $134.5 million at December 31, 2023.

Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute

Retrieved on: 
Thursday, February 29, 2024
Mycobacteroides abscessus, Urinary tract infection, Neisseria gonorrhoeae, Pyelonephritis, MCRI, Escherichia coli, Recce, RCE, Murdoch, Health, Streptococcus pneumoniae, Bacteria, ASX, AIR, Global Health, Organization, Partnership, Pharmaceutical industry

In 2023, Recce established its dedicated AIR Unit led by researcher Sohinee Sarkar, Ph.D., within MCRI’s state-of-the-art research facilities, underscoring the commitment of both organizations to drive innovation for anti-infective therapeutics.

Key Points: 
  • In 2023, Recce established its dedicated AIR Unit led by researcher Sohinee Sarkar, Ph.D., within MCRI’s state-of-the-art research facilities, underscoring the commitment of both organizations to drive innovation for anti-infective therapeutics.
  • “The partnership between Recce and MCRI will advance efforts and promote Australian leadership in the fight against antibiotic resistance.”
    The collaboration between Recce’s AIR Unit and MCRI exemplifies the power of partnership in driving medical breakthroughs.
  • As both organizations work together to advance anti-infective research, they remain committed to improving patient outcomes and addressing global health challenges.
  • James Graham, Chief Executive Officer of Recce Pharmaceuticals, added, “Our continued work at the AIR Unit aligns with Murdoch Children’s mission to address the global health threat of anti-microbial resistance through innovative research.

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Infection, AN2, Kidney, PK, IDSA, Infectious Diseases Society of America, Alcohol dehydrogenase, Impact, Therapy, NTM, Poster, Mycobacteroides abscessus, MAC, Genotype, ADH, Conference, Tablet, Patient, Pharmaceutical industry, Pharmacokinetics, Safety

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts.

Key Points: 
  • AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and three poster presentations at the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts.
  • AN2 Therapeutics is currently enrolling patients in the Phase 3 part of its pivotal Phase 2/3 clinical trial evaluating once-daily, oral epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease.
  • “We are excited to showcase our latest data at IDWeek 2023.
  • These results highlight epetraborole’s potent nonclinical activity against MAC isolates, as well as M. abscessus, another difficult-to-treat NTM pathogen.

European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Retrieved on: 
Tuesday, June 27, 2023
Civil service commission, Mycobacterium avium complex, Public, European Medicines Agency, COMP, Fever, Medicine, Mycobacteroides abscessus, Person, Cough, Government, Committee, EMA, U.S. FDA, MAC, NTM, Patient, European, Disease, European Commission, Fatigue, MAB, Pharmaceutical industry, EU

NTM is an orphan disease with limited approved therapies. Paratek’s scientific program exploring NUZYRA’s potential in the treatment of NTM includes an ongoing U.S. Phase 2b study -- the first randomized, placebo-controlled Phase 2b study of its kind -- in patients with NTM pulmonary disease caused by M. abscessus, as well as other studies ranging from in vitro to real-world evidence.

Key Points: 
  • The COMP opinion applies to all species of NTM, including Mycobacterium abscessus (MAB) and Mycobacterium avium complex (MAC).
  • Orphan designation in the European Union (EU) is granted by the European Commission within 30 days of a positive opinion being issued by the COMP.
  • Today’s standard of care for NTM typically involves a combination of multiple antibiotics, many of which are not approved for this disease.
  • Paratek is currently in discussions with potential partners to develop and commercialize NUZYRA in Japan and in Europe as a potential treatment for NTM.

Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million

Retrieved on: 
Tuesday, May 9, 2023
Spend, Partnership, SG, Regulation Fair Disclosure, Public, Programmer, Safety, Infection, Disclosure, EST, European Congress of Mathematics, ID, Government, Domestic, NTM, Operational efficiency, ECCMID, Patient, Mycobacteroides abscessus, Growth, R, Research, BARDA, Regulation, Video game, Pharmaceutical industry, Vaccine, Music, Fine chemical, Security (finance), Rare-earth element

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today reported financial results and provided an update on corporate activities for the first quarter ended March 31, 2023.

Key Points: 
  • Total revenue for the first quarter of 2023 was $31.2 million compared to $24.9 million for the same period in the prior year.
  • Total revenue for the first quarter of 2023 was comprised of the following:
    NUZYRA net U.S. sales of $26.2 million, which represented a 32% increase from $19.9 million for the same period in the prior year.
  • Research and development (R&D) expenses were $7.3 million for the first quarter of 2023, compared to $7.5 million for the same period in the prior year.
  • Selling, general and administrative (SG&A) expenses were $33.5 million for the first quarter of 2023, compared to $27.6 million for the same period in the year.

Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million

Retrieved on: 
Thursday, March 16, 2023
Annual report, SG, Rabbit, Survival, R, BARDA, Anthrax, Partnership, Regulation, Travel, Disclosure, Patient, Mycobacteroides abscessus, Government, Pharmaceuticals and Medical Devices Agency, COVID-19, Hand, Research, Post-exposure prophylaxis, Regulation Fair Disclosure, Growth, Medication, Collaboration, Bioterrorism, ID, NTM, EST, Pharmaceutical industry, Video game, Vaccine, Music, Cryptocurrency, Security (finance)

BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022. Paratek generated total revenue of $160.3 million, primarily as a result of strong growth in NUZYRA® commercial revenue. NUZYRA generated full-year net U.S. sales of $136.8 million in 2022, comprised of $98.7 million from the core commercial business, a 45% increase over the prior year, and $38.1 million from the second procurement of NUZYRA under the BARDA Project BioShield contract.

Key Points: 
  • Paratek generated total revenue of $160.3 million, primarily as a result of strong growth in NUZYRA® commercial revenue.
  • Total revenue for the fourth quarter of 2022 was $75.6 million compared to $31.8 million for the same period in the prior year.
  • Total revenue for the year ended December 31, 2022 was $160.3 million compared to $130.2 million for the prior year.
  • R&D expenses were $37.8 million for the year ended December 31, 2022, compared to $30.4 million in the prior year.